WPG Advisers’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$165K Buy
1,053
+150
+17% +$22.5K 0.1% 123
2026
Q1
$138K Buy
903
+482
+114% +$73.9K 0.1% 117
2025
Q4
$58K Buy
421
+206
+96% +$27K 0.04% 264
2025
Q3
$27.6K Hold
215
0.02% 434
2025
Q2
$26K Sell
215
-13
-6% -$1.47K 0.02% 428
2025
Q1
$25.4K Sell
228
-144
-39% -$15.3K 0.02% 416
2024
Q4
$36.2K Buy
+372
New +$39.7K 0.03% 347

Other funds holding NVS

WPG Advisers's NVS Position: Q2 2026 in Review

WPG Advisers increased its Novartis (NVS) stake by 17% in Q2 2026, buying an estimated $22.5K and bringing the position to 1,053 shares worth $165K. The position accounts for 0.1% of the portfolio, ranked #123.

WPG Advisers first reported a position in NVS in Q4 2024 and has held it in 7 quarters since. 1,027 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • WPG Advisers held 1,053 shares of Novartis worth $165K as of Q2 2026.
  • WPG Advisers bought 150 Novartis shares in Q2 2026, an estimated $22.5K.
  • Novartis made up 0.1% of WPG Advisers's portfolio in Q2 2026, its #123 holding.
  • WPG Advisers first reported a position in Novartis in Q4 2024 and has held it in 7 quarters since.
  • 1,027 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.